Tyra Biosciences

Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on profitability and cash flow metrics, reporting a GAAP EPS loss of $0.69 vs. the $0.65 mean expected. R&D spending surged to $39.2M to support the 'dabogratinib 3x3' strategy, driving a deeper-than-expected net loss of $45.6M compared to the $41.1M consensus. While the financial loss widened, the company extended its cash runway into 2H 2028 and confirmed critical Phase 2 data readouts for NMIBC in September 2026.